Clinical trials recruiting in Veldhoven, Netherlands
14
Recruiting trials
15
Conditions
Phase breakdown
Phase 2 4Phase 3 6Phase 4 1Not applicable 5
Conditions recruiting in Veldhoven, Netherlands
Recruiting trials in Veldhoven, Netherlands
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
- A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
- Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial
- Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation
- Control Crohn Safe Trial
- Feasibility of Remote eCTG Monitoring Home@Hospital in Complicated Pregnancies
- High-Risk prostatE Cancer radiatiOn Versus surgERy
- Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy
- Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- The TASTY-steering Study
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Common questions
How many clinical trials are recruiting in Veldhoven, Netherlands?
14 recruiting trials have at least one study site in Veldhoven, Netherlands.
Is this list complete?
No. For the full record, search ClinicalTrials.gov.